KUBTEC® Scientific Revolutionizes Preclinical Imaging with XCELL® TomoRad™

In a significant leap forward for preclinical research, KUBTEC® Scientific has officially launched the XCELL® TomoRad™ system, redefining the standards of image-guided radiation therapy (IGRT). This cutting-edge technology combines advanced 3D imaging techniques known as tomosynthesis, which captures multiple X-ray images from various angles. As a result, it reconstructs a highly detailed three-dimensional picture of the target area, presenting substantial advantages over traditional micro-CT imaging methods. The benefits include lower radiation exposure to samples, quicker image acquisition and reconstruction times, faster dosimetry, and reduced overall costs.

Before the introduction of TomoRad, accessing IGRT-capable systems often posed significant challenges due to their high costs and complex installation requirements. For many researchers, the barriers to entry were daunting, limiting the exploration and advancement of essential IGRT research. KUBTEC's team aimed to eliminate these obstacles, and the XCELL TomoRad system reflects their commitment to making IGRT more accessible to laboratories in need of advanced solutions.

A standout feature of this system is the patented Mag Mode™, a rapid dose administration method that automatically positions the sample close to the X-ray tube. This innovative feature enables the delivery of the highest dose in the least amount of time. For research laboratories with tight schedules, Mag Mode not only shortens treatment durations but also minimizes the period that subjects remain anesthetized, reducing stress levels for the animals involved.

Vikram Butani, CEO of KUBTEC Scientific, elaborated on the vision behind the XCELL TomoRad. He stated, "The entry barrier for researchers looking to delve into image-guided radiation was prohibitively high. Existing options were slow, costly, and complex, creating significant difficulties in balancing accuracy, efficiency, and ease of workflow. Our mission has always been to develop preclinical technologies that empower researchers to advance their work and ultimately lead to improved treatment quality in clinical settings. We anticipate that the XCELL TomoRad will pave the way for reduced radiation doses and faster treatment cycles for patients."

As KUBTEC Scientific continues to redefine the landscape of preclinical applications, their focus remains on devising transformative technologies that meet the needs of researchers and enhance the understanding of diseases. With over two decades at the forefront of imaging and radiation technology, KUBTEC is dedicated to providing a comprehensive range of systems tailored for disease investigation. Their proprietary technologies and software solutions offer essential tools for researchers aiming to answer complex scientific inquiries.

For more information about the XCELL® TomoRad™ image-guided radiation system, visit www.kubtecscientific.com.

About KUBTEC® Scientific

KUBTEC® Scientific is passionate about developing transformative technologies for preclinical applications. With over 20 years leading the field of X-ray imaging and radiation technology, they provide a wide variety of systems for disease investigation. Their innovative proprietary technologies and software solutions equip researchers with the necessary tools to tackle challenging questions in their disciplines.